NASDAQ:NKTR

Nektar Therapeutics Stock News

Healthcare > Biotechnology

Buy NKTR

*Your capital is at risk

$59.23

+0.670 (+1.14%)

At Close: Jun 03, 2026

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

11:01am, Thursday, 05'th Mar 2026

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar Therapeutics (NKTR) to Release Earnings on Thursday

01:18am, Thursday, 05'th Mar 2026

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) is anticipated to announce its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect the company to announce earnings of

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

06:00pm, Thursday, 26'th Feb 2026

SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 20

Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet

10:57am, Wednesday, 25'th Feb 2026

The mean of analysts' price targets for Nektar (NKTR) points to an 89.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Nektar Therapeutics to Participate in Two Investor Conferences in March

06:00pm, Tuesday, 24'th Feb 2026

SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference takin

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,879.00 in Stock

06:08am, Monday, 23'rd Feb 2026

Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) CEO Howard Robin sold 423 shares of the company's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an averag

Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy

08:16am, Wednesday, 18'th Feb 2026

Nektar Therapeutics (NKTR) is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable im

Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of “Moderate Buy” from Analysts

02:24am, Wednesday, 18'th Feb 2026

Shares of Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports.

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

07:00am, Tuesday, 17'th Feb 2026

SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

04:15pm, Friday, 13'th Feb 2026

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by